ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
Iduna Capital, Denmark
Title:The Silver Economy: Investing in the Technologies that Shape the Future of Aging
As the global population ages at an unprecedented rate, I believe we are standing at the crossroads
of one of the greatest challenges—and opportunities—of our time. By 2050, over 2 billion people will
be aged 60 and older, creating a massive economic shift known as the "Silver Economy." In my
presentation, I will explore how longevity biotechnology is addressing the root causes of aging and
transforming this demographic shift into a trillion-dollar opportunity.
I will discuss the groundbreaking advancements in cellular rejuvenation, gene editing, AI-driven drug
discovery, and regenerative medicine that are extending both healthspan and lifespan. Central to this
vision is the concept of Longevity Escape Velocity—the point at which scientific progress outpaces
aging, enabling radical life extension.
I will highlight how our thesis at Iduna Capital aligns with the goal of achieving LEV and why I believe
now is the time to invest in the future of aging. By showcasing the convergence of science,
technology, and market demand driving this revolution, my goal is to leave the audience inspired by
the transformative potential of longevity biotech and the role we can all play in shaping the future of
aging.
Peter Mathiesen is the Managing Partner at Iduna Capital, a venture capital rm focused on early-stage longevity-biotech investments. He supports transformative solutions that redene how we ageand how to extend healthspan.
Peter also runs Join Longevity, a newsletter that raises awareness about longevity science and inspires public engagement with the eld. Through actively sharing industry news and insights, as well as investing in breakthrough technologies, he addresses two major challenges in longevity awareness and funding.
With a Master’s degree in Innovation and Entrepreneurship in Biomedical Engineering from the University of Barcelona, Peter has led projects in aging-biomarker diagnostics and bacteriophage therapies.
Peter’s mission is to accelerate the development of technologies that redene aging, creating a future where longer, healthier lives are possible for everyone.